How the blood-vessel lining and oxidative stress affect microcirculation in chronic kidney disease
The Role of Glycocalyx and Oxidative Stress in Endothelial Function (Part 1)
This project will test whether changes in the blood-vessel lining (glycocalyx) and oxidative stress are linked to poorer small-vessel blood flow in people with chronic kidney disease compared with people who have high blood pressure and healthy volunteers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 105 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Josip Juraj Strossmayer University of Osijek Academic / other |
| Locations | 1 site (Osijek) |
| Trial ID | NCT07437729 on ClinicalTrials.gov |
What this trial studies
This is a cross-sectional observational study comparing people with hypertensive chronic kidney disease, people with hypertension without kidney damage, and healthy volunteers. Researchers will measure peripheral microcirculatory reactivity with a laser Doppler flow meter and glycocalyx thickness using Glycocheck. They will also analyze blood for soluble glycocalyx markers, oxidative stress and inflammation markers, PBMC findings, and antioxidant capacity. Results will be correlated to determine relationships between functional microvascular tests, glycocalyx status, and circulating markers.
Who should consider this trial
Good fit: Ideal candidates are adults with chronic kidney disease attributed to hypertension who are non-diabetic and non-smokers, along with comparison participants who have hypertension without kidney damage and healthy volunteers.
Not a fit: People with kidney disease from other causes, patients with diabetes, current smokers, or those with inflammatory or endocrine disorders are not likely to benefit or be eligible for this project.
Why it matters
Potential benefit: If successful, the work could identify biomarkers and mechanisms that explain endothelial dysfunction in CKD and suggest targets for better monitoring or future treatments.
How similar studies have performed: Previous smaller studies have linked glycocalyx damage and oxidative stress to endothelial dysfunction in CKD and cardiovascular disease, but translating these markers into routine clinical use remains unproven.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with CKD of hypertensive etiology (grades 1-2 and 3-5; eGFR CKD-EPI GFR ≥ 90 ml/min/1.73 m², i.e. \< 60 mL/min/1.73 m2), non-diabetics, non-smokers * patients with hypertension (according to ESH2023 Guidelines) without kidney damage (eGFR CKD-EPI \>90 mL/min/1.73 m2) non-diabetics, non-smokers * healthy volunteer subjects as controls Exclusion Criteria: * kidney disease of any other etiology except hypertension * endocrine, autoimmune or inflammatory diseases that could affect kidney function. * smoking * diabetes
Where this trial is running
Osijek
- Osijek University Hospital — Osijek, Croatia (Recruiting)
Study contacts
- Study coordinator: Ines Drenjančević, MD, PhD
- Email: ines.drenjancevic@mefos.hr
- Phone: +385912241406
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.